Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cDC1 vaccine
- Development stage
- Phase 2
- Lead developer
- Moffitt Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intrathecal
01
Overview
The cDC1 vaccine is an investigational autologous dendritic cell-based immunotherapy developed by the H. Lee Moffitt Cancer Center and Research Institute, in collaboration with Roswell Park Comprehensive Cancer Center. It is specifically designed to treat breast cancer leptomeningeal disease (LMD). The vaccine consists of type 1 conventional dendritic cells (cDC1s) that are pulsed with MHC class II peptides derived from HER2 and HER3 tumor antigens. By administering the vaccine intrathecally via an Ommaya reservoir, researchers aim to stimulate a robust Th1 CD4+ adaptive immune response directly within the cerebrospinal fluid, addressing the immune deficiency typically found in the leptomeningeal space. It is currently being evaluated in Phase 1 and Phase 2 clinical trials for patients with HER2-positive or triple-negative breast cancer LMD.
- Other names
- intrathecal cDC1 therapyDendritic Cell VaccineDCV
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on cDC1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cDC1 vaccine.